Assembly Biosciences (ASMB) Cash & Current Investments (2010 - 2026)

Assembly Biosciences' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $226.6 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 148.94% year-over-year to $226.6 million; the TTM figure through Mar 2026 stood at $226.6 million (up 148.94% YoY), while the FY2025 annual figure was $248.1 million, up 121.37% from the prior year.
• Cash & Current Investments was $226.6 million for Q1 2026 at Assembly Biosciences, down from $248.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $248.1 million in Q4 2025 to a low of $46.2 million in Q3 2023.
• Historically, Cash & Current Investments has averaged $120.7 million across 5 years, with a median of $109.2 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Cash & Current Investments plunged 57.47% in 2023, then soared 148.94% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $91.6 million in 2022, then soared by 42.18% to $130.2 million in 2023, then slipped by 13.95% to $112.1 million in 2024, then jumped by 121.37% to $248.1 million in 2025, then retreated by 8.67% to $226.6 million in 2026.
• The last three Cash & Current Investments figures came in at $226.6 million (Q1 2026), $248.1 million (Q4 2025), and $232.6 million (Q3 2025), per Business Quant data.